Sugi Predict

Sugi Predict / Compounds / SCHEMBL2071280

SCHEMBL2071280

SCHEMBL2071280

O=C(O)c1c(Cl)cccc1[N+](=O)[O-]

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 3/20 0.64
▸ L3MBTL1 Q9Y468 1/20 0.64
▸ TSHR P16473 1/20 0.50
▸ GPR35 Q9HC97 2/20 0.48
▸ HPGD P15428 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ VCAM1 P19320 2/20 0.45
▸ FEN1 P39748 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ APEX1 P27695 1/20 0.44
▸ FABP3 P05413 1/20 0.44
▸ FABP4 P15090 1/20 0.44
▸ POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11156407 0.98 TDP1 (0.62) TDP1L3MBTL1TSHRGPR35HPGD
SCHEMBL1554602 0.86 TDP1 (0.75) TDP1L3MBTL1TSHRGPR35MEN1
SCHEMBL793527 0.85 ALDH1A1 (0.61) TDP1L3MBTL1TSHRGPR35HPGD
SCHEMBL27511511 0.84 VCAM1 (0.60) TDP1L3MBTL1TSHRGPR35HPGD
SCHEMBL25170030 0.84 TDP1 (0.53) TDP1L3MBTL1TSHRGPR35HPGD
SCHEMBL11854478 0.84 TDP1 (0.49) TDP1L3MBTL1TSHRGPR35HPGD
SCHEMBL3503761 0.84 TDP1 (0.53) TDP1L3MBTL1TSHRGPR35HPGD
SCHEMBL793981 0.84 TDP1 (0.49) TDP1L3MBTL1TSHRGPR35HPGD
SCHEMBL16862931 0.83 TDP1 (0.52) TDP1L3MBTL1TSHRMEN1KMT2A
Hydrogen Sulfide SCHEMBL28004578 0.82 TDP1 (0.70) TDP1L3MBTL1TSHRGPR35MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115041159-A 2-chloro-6-nitrobenzoic acid catalyst and preparation method and application thereof 常州新日催化剂股份有限公司 2022-09-13 — — CN claimed
CN-105621587-B A kind of method using potentiometric titrations degradating chloro nitro-aromatic 浙江大学 2018-01-23 — — CN claimed
CN-105621587-A Method for degrading chloro-nitroaromatic by using sulfate radicals UNIV ZHEJIANG 2016-06-01 — — CN claimed
JP-6293700-A — — None — — JP disclosed
CN-119192007-A Preparation method of 2-chloro-6-aminobenzoic acid 陕西蒲城万德科技有限公司 2024-12-27 — — CN disclosed
CN-117736192-A PI3K/HDAC dual inhibitor and application thereof 安徽中医药大学 2024-03-22 — — CN disclosed
US-20230348363-A1 COMPOUNDS AND THEIR USE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-11-02 — — US disclosed
EP-4259605-A1 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE Astrazeneca AB (SE) 2023-10-18 — — EP disclosed
CN-116547270-A 4- (2-fluoro-4-methoxy-5-3- (((1-methylcyclobutyl) methyl) carbamoyl) bicyclo [2.2.1] hept-2-yl) carbamoyl) phenoxy) -1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as RXFP1 modulators for the treatment of heart failure 阿斯利康(瑞典)有限公司 2023-08-04 — — CN disclosed
US-11667602-B2 Compounds and their use ASTRAZENECA AB (SE) 2023-06-06 — — US disclosed
CN-116096710-A 4-oxo-3, 4-dihydroquinazolinone compounds for the treatment of BRAF related diseases and disorders 阿雷生物药品公司 2023-05-09 — — CN disclosed
US-5198575-A PREPARATION OF NITROBENZOIC AND ANTHRANILIC ACIDS BASF AKTIENGESELLSCHAFT (DE) 1993-03-30 — — US disclosed
EP-0529426-A2 Process for the preparation of nitrobenzoic and anthranilic acids BASF Aktiengesellschaft (DE) 1993-03-03 — — EP disclosed
EP-0081157-B1 PROCESS FOR THE PREPARATION OF N-NITROARYL-NITROARYL CARBOXAMIDES BAYER AG (DE) 1985-01-02 — — EP disclosed
US-4473650-A Use of strong organic acid polyelectrolyte salts in test means, test device and method for determining the ionic strength or specific gravity of a liquid sample MILES LABORATORIES, INC. (US) 1984-09-25 — — US disclosed
EP-0038458-B1 4-HYDROXY-1,2-BENZISOTHIAZOL-3(2H)-ONE-1,1-DIOXIDE, THEIR SALTS, THEIR PREPARATION AND THEIR UTILIZATION Dr. Karl Thomae GmbH (DE) 1983-09-21 — — EP disclosed
US-4404230-A ARTICIFIAL SWEETENERS DR. KARL THOMAE GMBH (DE) 1983-09-13 — — US disclosed
EP-0081157-A1 Process for the preparation of N-nitroaryl-nitroaryl carboxamides BAYER AG (DE) 1983-06-15 — — EP disclosed
US-4306074-A Preparation of a mixture of an alkyl 3-chloroanthranilate and an alkyl 6-chloroanthranilate BASF AKTIENGESELLSCHAFT (DE) 1981-12-15 — — US disclosed
EP-0038458-A1 4-Hydroxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide, their salts, their preparation and their utilization Dr. Karl Thomae GmbH (DE) 1981-10-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11667602-B2 Compounds and their use RXFP1, RXFP3, RXFP2 TDP1 4386/4885L3MBTL1 872/4885TSHR 436/4885
US-20230348363-A1 COMPOUNDS AND THEIR USE RXFP1, RXFP3, RXFP2 TDP1 4386/4885L3MBTL1 872/4885TSHR 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.